(Q80748144)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

title

Interferon beta in multiple sclerosis: how much BENEFIT? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

Sean J Pittock

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

1 August 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

370

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

9585

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

363-364

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

Not every patient with multiple sclerosis should be treated at time of diagnosis

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Disability progression in multiple sclerosis is slower than previously reported.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

How much can we learn from long-term extension trials in multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

Neuroepidemiology. Part II: Assessment of therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961170-2

7 January 2021

10.1016/S0140-6736(07)61170-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17678997%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference